论文部分内容阅读
目的探讨尿激酶联合阿托伐他汀治疗ST段抬高型心肌梗死的临床疗效。方法选取介休市人民医院2014年1月—2015年1月收治的50例ST段抬高型心肌梗死患者,随机分成对照组和试验组,各25例。对照组行常规心肌梗死治疗,试验组在对照组基础上行尿激酶联合阿托伐他汀治疗,比较两组患者的临床疗效、血脂水平及不良反应发生情况。结果试验组总有效率高于对照组,三酰甘油、低密度脂蛋白胆固醇、总胆固醇水平低于对照组,高密度脂蛋白胆固醇水平高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论尿激酶联合阿托伐他汀治疗ST段抬高型心肌梗死的临床疗效显著,可明显改善患者的血脂代谢,从而有效保障患者的生活质量。
Objective To investigate the clinical efficacy of urokinase combined with atorvastatin in the treatment of ST-segment elevation myocardial infarction. Methods Fifty patients with ST-elevation myocardial infarction who were admitted to the People’s Hospital of Jiexiu from January 2014 to January 2015 were randomly divided into control group and experimental group, with 25 cases in each group. The control group was treated with conventional myocardial infarction. The experimental group was treated with urokinase combined with atorvastatin on the basis of the control group. The clinical efficacy, blood lipid levels and adverse reactions of the two groups were compared. Results The total effective rate of the experimental group was higher than that of the control group, triglyceride, low density lipoprotein cholesterol, total cholesterol level was lower than the control group, high-density lipoprotein cholesterol level was higher than the control group, the incidence of adverse reactions was lower than the control group, the difference There was statistical significance (P <0.05). Conclusion The clinical efficacy of urokinase combined with atorvastatin in the treatment of ST-elevation myocardial infarction is significant, which can significantly improve the blood lipid metabolism of patients and thus effectively guarantee the quality of life of patients.